Guess? Inc. (GES - Free Report) posted fourth-quarter fiscal 2020 results with earnings beating the Zacks Consensus Estimate for the fourth straight time. Also, the top and the bottom line increased year over year. Revenues in the quarter were backed by strength in Europe and licensing businesses. Notably, shares of the company rallied 20.4% in the after-hours trading session on Mar 18.
However, the company refrained from providing guidance for fiscal first quarter ending May 2, and fiscal year ending Jan 30, 2021, given the coronavirus outbreak and its unpredictable impact on the company’s performance. Moreover, management resorted to temporary closures in major regions worldwide.
Quarter in Detail
Guess? posted adjusted earnings of $1.22 per share, which surpassed the Zacks Consensus Estimate of $1.12 and increased 74.3% from the year-ago quarter’s figure. The upside can be attributed to higher revenues and gross margin.
Net revenues amounted to $842.3 million that missed the consensus mark of $851.3 million. However, the top line inched up 0.6% year over year. On a constant-currency (cc) basis, revenues moved up 1.8%.
The company’s gross margin expanded 360 basis points (bps) to 40.2%, owing to increased initial markups (IMUs).
Also, adjusted operating profit came in at $101.7 million, up 32.2% year over year. Adjusted operating margin expanded 290 bps from the year-ago quarter’s figure to 12.1%. The uptick was led by lower logistics costs in Europe along with greater initial markups in Americas Retail and Europe.
Revenues in the Americas Retail segment declined 4.1% year over year and 4.4% at cc. Retail comp sales, including e-commerce, declined 3% each on a year-over-year basis and at cc due to negative traffic.
Net revenues in the Americas Wholesale segment declined 3% (down 3.8% at cc), thanks to the timing of shipments.
The Europe segment's revenues increased 13.2% (up 15.8% at cc). Store openings, improvement in wholesale revenues and comps growth boosted the region’s performance. Retail comp sales, including e-commerce, inched up 1% year over year and rose 3% at cc. This marks the 18th successive quarter of positive comps for the European region.
Asia revenues declined 27.7% (down 26.4% at cc). Retail comp sales, including e-commerce, lost 26% (down 25% at cc) due to soft softness across all major markets including China, Korea and Japan.
Licensing revenues increased 22.7%.
The company exited the quarter with cash and cash equivalents of $284.6 million as well as long-term debt and finance lease obligations of $32.8 million. Further, stockholders’ equity was $639.7 million. Net cash provided by operating activities during fiscal 2020 amounted to $197.9 million.
Apart from the accelerated share repurchase program, the company repurchased nearly 6.1 million shares for $118.1 million in fiscal 2020, including repurchases of nearly 0.3 million shares (for $7.5 million) in the fourth quarter.
In view of the coronavirus outbreak, management decided to postpone the announcement of any quarterly cash dividend for first quarter of fiscal 2021.
Shares of this Zacks Rank #5 (Strong Sell) company have slumped 77.4% in the past six months compared with the industry’s decline of 35.4%.
Top 3 Picks
Deckers Outdoor Corporation (DECK - Free Report) , with a Zacks Rank #2 (Buy), has a long-term earnings per share (EPS) growth rate of 12.4%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Netflix, Inc. (NFLX - Free Report) , with a Zacks Rank #2 (Buy), has a long-term EPS growth rate of 30%
G-III Apparel Group (GIII - Free Report) , with a Zacks Rank #2, has a long-term EPS growth rate of 11.4%.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>